Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function Yanke YuJustin HoffmanDiane Wang Original Article 10 October 2020 Pages: 701 - 710
Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation Senthil Velan BhoopalanShane J. CrossBrandon M. Triplett Original Article 10 October 2020 Pages: 711 - 717
Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration Sufeng ZhouWei LiuFeng Shao Original Article 12 October 2020 Pages: 719 - 730
The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis Chen YeAbuduhaibaier SadulaDianrong Xiu Original Article 12 October 2020 Pages: 731 - 740
Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors Eryk LatochKatarzyna KonończukMaryna Krawczuk-Rybak Original Article Open access 14 October 2020 Pages: 741 - 749
Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients Mads Kingo Guldberg HansenMaja Patricia SmerdelKarina Dahl Steffensen Original Article 16 October 2020 Pages: 751 - 759
Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer Zhen ZhangLuoyan ZhangChi Zhang Original Article 17 October 2020 Pages: 761 - 772
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma Xiang-Rong NiCheng-Cheng GuoZhong-Ping Chen Original Article 19 October 2020 Pages: 773 - 782
The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo Tangwu ZhongChuanke ZhaoChengchao Shou Original Article Open access 21 October 2020 Pages: 783 - 792
Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal®) in glioma patients in China Chaoying HuQingtang LinLan Zhang Original Article 21 October 2020 Pages: 793 - 801
Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma Kojiro HataKimitaka SuetsuguIchiro Ieiri Original Article 23 October 2020 Pages: 803 - 813
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors Khanh T. DoGeraldine O’Sullivan CoyneGeoffrey I. Shapiro Original Article 23 October 2020 Pages: 815 - 827
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212) Emily GreengardYael P. MosseBrenda J. Weigel Clinical Trial Report 23 October 2020 Pages: 829 - 840
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma Maria Christina CoxMarta BanchiGuido Bocci Short Communication 18 October 2020 Pages: 841 - 846